Navigation Links
The SFJ Pharmaceuticals Group Announces Agreement With Pfizer to Co-develop Dacomitinib as First-Line Treatment for Patients With Advanced Non-small Cell Lung Cancer
Date:9/7/2012

SAN FRANCISCO, September 7, 2012 /PRNewswire/ --

Phase 3 Trial to be Conducted Across Sites in Asia and Europe

The SFJ Pharmaceuticals Group (SFJ), announced today that it has entered into a collaborative development agreement with Pfizer Inc. to conduct a Phase 3 clinical trial of Pfizer's investigational pan-HER (pan-human epidermal growth factor receptor) inhibitor, dacomitinib (PF-00299804).  The trial, which will be conducted across multiple sites in Asia and Europe, will evaluate dacomitinib as a first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of epidermal growth factor receptor (EGFR).

Under the terms of the agreement, SFJ will provide the funding and clinical development supervision to generate the clinical data necessary to support a registration dossier on dacomitinib for marketing authorization by regulatory authorities for the indication: First-line treatment of patients with locally advanced or metastatic NSCLC with EGFR activating mutations.  If approved for this indication, SFJ will be eligible to receive milestone payments and earn-out payments.

This is the second collaborative agreement between SFJ and Pfizer.  SFJ previously entered into an agreement with Pfizer to conduct a Phase 3 trial in Asia of Pfizer's Inlyta® (axitinib) for the adjuvant treatment of patients at high risk of recurrent renal cell carcinoma following nephrectomy.

"At SFJ, our mission is to accelerate the availability of new and innovative drugs into the world's major markets through co-development," said Robert DeBenedetto, SFJ's President & CEO.  "With this important, multi-national trial, we are pleased to continue our collaborative relationship with Pfizer and support the clinical development of a promising new agent for the treatment of lung cancer."

"Pfizer is committed to building innovative partnerships that enable us to advance our clinical development programs and deliver new cancer medicines to patients as efficiently as possible around the world," said Garry Nicholson, president and general manager, Pfizer Oncology. "Non-small cell lung cancer remains a difficult disease to treat despite recent advances, and Pfizer is evaluating dacomitinib in NSCLC across lines of therapy and a range of histologies and molecular subtypes.  By collaborating with SFJ on the continued clinical development of dacomitinib in this patient population, we hope to more immediately bring a new first-line therapy to patients in need."

Dacomitinib is an oral, once-daily, small molecule inhibitor of HER-1 (EGFR), HER-2 and HER-4 tyrosine kinases.  It is being evaluated by Pfizer in a comprehensive clinical development program that includes two global, randomized Phase 3 clinical trials investigating its safety and efficacy as a second-line and refractory treatment for NSCLC.  Dacomitinib has not been approved by any regulatory agency.  

About the SFJ Pharmaceuticals Group
The SFJ Pharmaceuticals Group, which was formed in January of 2009 is a global drug development group of companies, which provides a unique co-development partnering model for some of the world's top pharmaceutical and biotechnology companies.  SFJ uses its financial strength and core team of pharmaceutical development experts to provide highly customized partnering models in which SFJ provides the funding and clinical development supervision, necessary to obtain regulatory approval for some of the most promising drug development programs of Pharmaceutical and Biotechnology companies. SFJ is backed by Abingworth, Clarus and Fintech, which are venture capital firms specializing in bio-pharmaceutical development. Collectively these venture capital firms manage over USD $2.5 billion in funding.

http://www.abingworth.com


'/>"/>
SOURCE SFJ Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Companys Ongoing Phase I/II Trial in Acute Myeloid Leukemia
2. Jazz Pharmaceuticals Announces Participation At The 2012 Morgan Stanley Global Healthcare Conference In New York On September 11
3. Cumberland Pharmaceuticals to Present at the UBS Global Life Sciences Conference in New York
4. Actinium Pharmaceuticals Stockholders Vote to Approve Fundraising and Public Listing
5. Global Markets for Membrane Technology for Pharmaceuticals
6. Inovio Pharmaceuticals Takes Major Stride Toward Universal Influenza Vaccine
7. Jazz Pharmaceuticals Enters Definitive Agreement to Sell its Womens Health Business to Meda
8. Avanir Pharmaceuticals Announces Publication Of PBA Burden Of Illness Study
9. Savient Pharmaceuticals to Present at the 6th Annual Imperial Capital Global Opportunities Conference
10. Questcor Pharmaceuticals to Present at Investor Conferences in September
11. Intercept Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Oct. 11, 2017  Caris Life Sciences ® , ... the promise of precision medicine, today announced that St. ... Precision Oncology Alliance™ (POA) as its 17 th ... St. Jude Crosson Cancer Institute will help develop standards ... of tumor profiling, making cancer treatment more precise and ...
(Date:10/10/2017)... EXTON, Pa. , Oct. 10, 2017   ... leader in innovative solutions for injectable drug administration, today ... of West,s ID Adapter for improving the intradermal administration ... the Fourth Skin Vaccination Summit in May 2017 by ... Team Lead, Polio Department, World Health Organization (WHO), and ...
(Date:10/4/2017)... Mass. , Oct. 4, 2017  According to the Centers for ... the end of October . PhysicianOne Urgent Care is helping communities across ... Westchester, NY , by offering no-cost* flu shots through the ... as mandated by certain health insurance regulations. ... The best time to get a flu shot is by the ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids ... sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited ... all ages; it is a non-competitive, non-timed event, which is all about having fun ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the ... published author, William Nowers. Captain Nowers and his wife, Millie, have six children, ... in the Navy. Following his career as a naval aviator and carrier pilot, ...
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... HMP ... the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare ... City on October 11, 2017. , The annual award competition recognizes editorial and design ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... in property taxes a year. In some states—like New York, New Jersey, Massachusetts, ... contrast, many overseas retirement havens have extremely low property-tax rates, which contributes to ...
Breaking Medicine News(10 mins):